Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | TOP2A | P11388 | 7/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 7/20 | 0.43 |
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8692136 | 0.89 | ADRB2 (0.47) | ADRB2TOP2ATOP2BSTAT3KDM4E | |
| SCHEMBL7503528 | 0.86 | ADRB2 (0.40) | ADRB2TOP2ATOP2B | |
| SCHEMBL12836412 | 0.84 | ADRB2 (0.49) | ADRB2TOP2ATOP2BSTAT3TSHR | |
| SCHEMBL12836620 | 0.84 | ADRB2 (0.50) | ADRB2TOP2ATOP2BSTAT3TSHR | |
| SCHEMBL12836413 | 0.84 | ADRB2 (0.48) | ADRB2TOP2ATOP2BSTAT3TSHR | |
| SCHEMBL7841318 | 0.83 | TOP2A (0.55) | TOP2ATOP2BKDM4EHPGDPOLB | |
| SCHEMBL8435344 | 0.83 | ADRB2 (0.60) | ADRB2TOP2ATOP2BSTAT3POLB | |
| SCHEMBL5704396 | 0.82 | ADRB2 (0.64) | ADRB2TOP2ATOP2BSTAT3KDM4E | |
| SCHEMBL2844967 | 0.81 | ADRB2 (0.68) | ADRB2TOP2ATOP2BSTAT3KDM4E | |
| SCHEMBL29492858 | 0.81 | ADRB2 (0.68) | ADRB2TOP2ATOP2BSTAT3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | PETERSEN UWE (DE) | 2001-11-01 | — | — | US | disclosed |
| US-6288081-B1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | OXER1, AOC3, PAM | ADRB2 2223/4885TOP2A 156/4885TOP2B 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.